Please enable JavaScript.
Coggle requires JavaScript to display documents.
LGC Seracare, Liquid biopsy, Solid tumours, Competition, NIPT testing,…
LGC Seracare
-
-
-
Our sales
-
Not doing as well with reproductive health standards
patient derived cfDNA material
-
-
-
Growth
We are on track for 25-30% growth,
second to Germany
-
Product design
Plasmid design
Linearised DNA plasmids for SNVs,
INDELs, CNVs and SVs
-
-
-
-
Liquid biopsy
-
Solid tumour ctDNA products
- ctDNA mix v2 / plasma
- ctDNA complete mix / plasma (17% of sales)
- ctDNA MRD panel mix
-
-
Seraseq ctDNA MRD panel
To develop, validate & monitor the performance of tumour informed MRD assays in cancer patient undergoing therapy
-
ctDNA extraction reference material
Evaluate, optimise and monitor
efficiency of cfDNA extrations & its
impact on variant detection in LB samples
Solid tumours
Tumour mutation burden (TMB)
number of somatic mutations
Patients with TMP score > 10 responsd better to immune checkooint inhibitors
There is a need for reference materials to align
TMB scores determined by disparate NGS panels
and WES
-
If someone wants to buy the Breast CNV mix or the Lung & Brain CNV mix - these are being discontinued so direct them to the solid tumour CNV mix instead
Fusion genes
Much easier to detect the resulting fusion transcript so LGC fusion standards are mostly RNA
Popular products
Fusion V4 RNA mix & FFPE (12% of sales)
Whole transcriptome RNA seq mix (mostly preclinical)
NTRK Fusion RNA mix & FFPE
-
Homologous Recombination Deficiency (HRD)
Dysfunctional HR genes result in genomic instability and tumourigenesis
HRD+ tumours rely on PARP pathway for tumour growth - sensitive to PARPi therapy
Products
Seraseq HRD Reference Materials:
high positive, low positive & negative
There is a nice webinar which explains HRD, ways of detecting it and how to use reference materials - she will find this for us
BRCA1/2 LGR reference materials
20 gene variants
Available as FFPE or purified gDNA material for somatic NGS assays
-
-
Competition
3rd party vendors
- Horizon, Thermo, Coriell, other cell line banks
Horizon/Revvity top competitor.
- Mixture of CRISPR engineered cell lines
- Fewer CNVs, complex variants and RNA fusions
- Oncospan - highly multiplexed, not content not clinically relevant
- cfDNA products often at too high VAFs for liquid biopsy
- Several recent product launches (cfDNA and FFPE)
SensID
- Limited portfolio and variant content
- ESR1, CE-IVD MSI
- Aggressive custom pricing
One to keep an eye on
Thermo
- Biosynthetic DNA spike ins
- Limited portfolio
Twist Biosciences
- Biosynthetic DNA spike ins
- Not focused in clinical diagnostics - mostly people using their panels might use their controls
-
Home brews
- Using remnant clinical samples
- In-house created mixes from research-use cell lines
Do nothing
Do not use any sample controls, only use built in seq controls
-
Oncology products
-
Heme disorder products
Leukemia/lymphoma
- Myeloid mutation DNA mix (12% of sales)
- Myeloid fusion RNA mix (8% of sales, no competitors)
- Lymphoma DNA mix & FFPE